newsfilter
← Latest News
Business Wire·

Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights

-- Presented preliminary data from a May 1, 2025 data cutoff date for all 117 patients with a median follow-up of 12.6 months in the Phase 2 pivotal iMMagine-1 study of anito-cel in patients with RRMM -- -- 97% ORR,